European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42%   AZN, -1.26% said it’s pay...

Immix Biopharma’s stock rockets after pediatric cancer treatment granted RPD by the FDA

Shares of Immix Biopharma Inc. IMMX, +9.20% rocketed 66.0% in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease (RPD) designation by the...